國家級五大癌症篩檢計畫 The National Five Major Cancer Screening Programs

政策、方案與公衛影響 Policy, Programs, and Public Health Impact

第一節：五大篩檢方案深度解析 Section 1: In-depth Analysis of the Five Screening Programs

本節將對五項癌症篩檢計畫的執行方案進行精細的拆解與分析，確立其作為國家級公共衛生標準的科學依據與操作規範。 This section will provide a detailed breakdown and analysis of the implementation plans for the five cancer screening programs, establishing their scientific basis and operational standards as a national public health initiative.

1.1 乳癌篩檢 1.1 Breast Cancer Screening

採用「乳房X光攝影檢查」（Mammography），能精確偵測微小腫瘤與微鈣化點，是目前唯一證實能有效降低乳癌死亡率的篩檢工具。 Utilizes Mammography, which can accurately detect tiny tumors and microcalcifications. It is currently the only screening tool proven to effectively reduce breast cancer mortality.

• 官方補助資格：年齡介於40歲至74歲的女性，每2年可接受1次免費篩檢。Official Eligibility: Women aged 40 to 74 are eligible for one free screening every 2 years.
• 篩檢前程序：建議穿著兩件式服裝，檢查當日避免在腋下或乳房塗抹體香劑、爽身粉或乳液，並避開經期前一週受檢以減少不適。Pre-screening Procedure: It is recommended to wear a two-piece outfit. On the day of the exam, avoid applying deodorant, talcum powder, or lotion to the underarms or breasts. Avoid scheduling the exam in the week before your menstrual period to reduce discomfort.

1.2 子宮頸癌篩檢 1.2 Cervical Cancer Screening

採雙軌策略，結合細胞學與病毒學檢測，以提升篩檢的精準度。 Adopts a dual-track strategy, combining cytology and virology testing to enhance screening accuracy.

• 篩檢方法：Screening Methods:
  • 子宮頸抹片檢查 (Pap Smear)：透過顯微鏡觀察子宮頸剝落細胞，偵測癌前病變。Pap Smear: Detects precancerous lesions by examining exfoliated cervical cells under a microscope.
  • 人類乳突病毒 (HPV) 檢測：直接偵測是否存在致癌的高風險型病毒(hr-HPV)。Human Papillomavirus (HPV) Test: Directly detects the presence of high-risk, cancer-causing HPV types (hr-HPV).
• 官方補助資格：Official Eligibility:
  • 抹片檢查：25-29歲女性每3年1次；30歲以上女性每年1次（建議至少每3年1次）。Pap Smear: Women aged 25-29, once every 3 years; women aged 30 and over, once a year (recommended at least every 3 years).
  • HPV檢測：針對35歲、45歲及65歲女性，提供一次性補助。HPV Test: A one-time subsidy is provided for women at ages 35, 45, and 65.
• 篩檢前程序：檢查前應避免盆浴、沖洗陰道、使用陰道塞劑、前一夜的性行為，並避開月經期間。Pre-screening Procedure: Before the test, avoid douching, using vaginal suppositories, sexual intercourse the night before, and schedule it outside of your menstrual period.

1.3 大腸癌篩檢 1.3 Colorectal Cancer Screening

採用「定量免疫法糞便潛血檢查」（FIT），是一種非侵入性、操作簡便的工具，專門偵測糞便中的微量血液，準確性高且不受飲食干擾。 Utilizes the Fecal Immunochemical Test (FIT), a non-invasive, easy-to-use tool that specifically detects trace amounts of blood in the stool. It is highly accurate and unaffected by diet.

• 官方補助資格：Official Eligibility:
  • 一般風險：45歲至74歲民眾，每2年1次。Average Risk: Individuals aged 45 to 74, once every 2 years.
  • 高風險：40歲至44歲且一等親有大腸癌史者，每2年1次。High Risk: Individuals aged 40 to 44 with a first-degree relative with colorectal cancer, once every 2 years.
• 篩檢前程序：無需禁食或改變飲食。若有痔瘡出血等問題，建議待症狀穩定後再篩檢。Pre-screening Procedure: No fasting or dietary changes are required. If issues like hemorrhoid bleeding are present, it is advised to wait until symptoms stabilize before screening.

1.4 口腔癌篩檢 1.4 Oral Cancer Screening

由醫師透過視診與觸診進行「口腔黏膜檢查」，目的是早期發現白斑、紅斑等癌前病變。此篩檢採「風險因子導向」，精準鎖定高風險族群。 Conducted by a physician via visual inspection and palpation, the “Oral Mucosa Examination” aims to detect precancerous lesions such as leukoplakia and erythroplakia early. This screening is “risk-factor oriented,” precisely targeting high-risk populations.

• 官方補助資格（每2年1次）：Official Eligibility (once every 2 years):
  • 30歲以上，有嚼食檳榔（含已戒除）或吸菸習慣的民眾。Age 30 and over with a habit of chewing betel quid (including former users) or smoking.
  • 18歲以上，有嚼食檳榔（含已戒除）習慣的原住民。Age 18 and over for indigenous people with a habit of chewing betel quid (including former users).
• 策略意涵：此「風險分層」策略將有限資源集中投放於最需要的人群，極大化篩檢的成本效益。Strategic Implication: This “risk stratification” strategy concentrates limited resources on the populations most in need, maximizing the cost-effectiveness of the screening.

1.5 肺癌篩檢 1.5 Lung Cancer Screening

採用「低劑量胸部電腦斷層掃描」（LDCT），能偵測到傳統X光無法發現的微小肺部結節，是早期發現肺癌的利器。 Utilizes Low-Dose Computed Tomography (LDCT) of the chest, which can detect tiny pulmonary nodules invisible on a conventional X-ray, making it a powerful tool for early lung cancer detection.

• 官方補助資格（每2年1次）：Official Eligibility (once every 2 years):
  • 具肺癌家族史：男性45-74歲，或女性40-74歲，其一等親有肺癌史。Family history of lung cancer: Males aged 45-74 or females aged 40-74 with a first-degree relative with lung cancer.
  • 重度吸菸史：50-74歲，吸菸史達20包-年以上，且仍在吸菸或戒菸未滿15年者。Heavy smoking history: Aged 50-74 with a smoking history of 20 pack-years or more, and who are still smoking or have quit for less than 15 years.
• 排除標準：懷孕婦女、12個月內做過胸部CT、曾確診肺癌者等不適用。Exclusion Criteria: Not applicable to pregnant women, individuals who have had a chest CT within the last 12 months, or those with a previous diagnosis of lung cancer.

表一：台灣國家級五大癌症篩檢方案總覽（截至2025年）Table 1: Overview of Taiwan’s Five National Cancer Screening Programs (as of 2025)

第二節：民眾參與路徑：從篩檢到確診管理 Section 2: The Public Participation Pathway: From Screening to Diagnosis Management

本節將闡述此計畫的實際運作框架，說明政策如何轉化為具體的民眾服務流程，特別是篩檢結果異常時的關鍵後續處理機制。 This section will elaborate on the operational framework of the program, explaining how policy is translated into concrete public service procedures, especially the critical follow-up mechanisms for abnormal screening results.

2.1 參與計畫的多元管道 2.1 Diverse Channels for Participation

國健署建立了多元化的參與管道，確保民眾能便捷地獲得服務。 The HPA has established diverse participation channels to ensure convenient access to services for the public.

• 常規醫療院所：持健保卡至全國特約醫療院所即可接受篩檢。Contracted Medical Institutions: Screenings are available at contracted healthcare facilities nationwide by presenting the NHI card.
• 數位化資訊平台：可透過國健署網站或「全民健保行動快易通APP」查詢據點與接收提醒。Digital Information Platforms: Locations can be found and reminders received through the HPA website or the “NHI Express” mobile app.
• 社區外展服務：如苗栗縣衛生局協辦的「大型整合性篩檢活動」，深入社區提供一站式服務，並以獎勵品提高參與意願，展現了將公衛服務主動送達民眾的積極作為。Community Outreach Services: Such as the “Large-Scale Integrated Screening Events” co-organized by the Miaoli County Public Health Bureau, which provide one-stop services deep within communities and use incentives to increase participation, demonstrating a proactive approach to delivering public health services.

2.2 篩檢結果異常的關鍵後續追蹤路徑 2.2 Critical Follow-Up Pathway for Abnormal Results

篩檢的最終目的不僅是發現異常，更是確保個案能獲得及時的診斷與治療。為此，計畫建立了一套嚴謹的管理系統。 The ultimate goal of screening is not just to detect abnormalities but to ensure that cases receive timely diagnosis and treatment. To this end, the program has established a rigorous management system.

• 「主動追陽」系統：這是計畫最核心的環節之一。研究顯示，糞便潛血陽性者若延遲超過一年才做大腸鏡，罹患晚期大腸癌的風險是及時檢查者的2.8倍。為此，系統由「癌症個案管理師」主動聯繫陽性個案，提供支持、協助安排回診，確保照護的連續性。Proactive Follow-up System for Positive Cases: This is a core component. Studies show that individuals with a positive FIT who delay colonoscopy for more than a year have a 2.8 times higher risk of advanced colorectal cancer. Thus, the system employs “Cancer Case Managers” to proactively contact positive cases, provide support, and arrange follow-up appointments, ensuring continuity of care.
• 制度化管理：健保署為此提供給付，要求醫療院所必須在規定時限內完成追蹤（如大腸癌90天、乳癌60天），將「追陽」從建議轉化為有標準、可稽核的流程。Institutionalized Management: The NHIA provides reimbursement for this, requiring medical institutions to complete follow-ups within specified timeframes (e.g., 90 days for colorectal cancer, 60 days for breast cancer), transforming follow-up from a suggestion into a standardized, auditable process.
• 標準化確診流程：針對不同篩檢的陽性結果，皆有清晰的標準化確診路徑（如下表）。Standardized Diagnostic Procedures: Clear, standardized diagnostic pathways exist for positive results from different screenings (as shown below).

表二：篩檢結果異常之標準化後續確診方案Table 2: Standardized Follow-up Diagnostic Plans for Abnormal Screening Results

第三節：計畫成效、政策演進與未來展望 Section 3: Program Effectiveness, Policy Evolution, and Future Outlook

本節將從宏觀角度評估此篩檢計畫的成效，分析其作為一項國家衛生政策的演進軌跡，並提出專業的綜合評估。 This section will evaluate the effectiveness of the screening program from a macro perspective, analyze its evolutionary trajectory as a national health policy, and provide a professional comprehensive assessment.

3.1 衡量成功：數據驅動的公衛勝利 3.1 Measuring Success: A Data-Driven Public Health Victory

此計畫的成效有堅實的數據支持，證明其在拯救生命上的巨大價值。 The effectiveness of this program is supported by solid data, demonstrating its immense value in saving lives.

• 顯著降低死亡率：規律篩檢可降低大腸癌死亡率35%、乳癌41%、子宮頸癌70%、口腔癌26%。Significant Mortality Reduction: Regular screening can reduce mortality from colorectal cancer by 35%, breast cancer by 41%, cervical cancer by 70%, and oral cancer by 26%.
• 大幅提升存活率：篩檢的關鍵作用在於「早期發現」。以大腸癌為例，早期（0-1期）5年存活率高達90%以上，晚期（4期）則驟降至20%以下。Substantial Increase in Survival Rates: The key role of screening is “early detection.” Taking colorectal cancer as an example, the 5-year survival rate for early-stage (0-1) is over 90%, while it drops to below 20% for late-stage (4).
  • 驚人成效：透過篩檢發現的大腸癌個案中，高達93.4%屬於預後極佳的癌前病變或早期癌症。Impressive Results: Among colorectal cancer cases detected through screening, as high as 93.4% are precancerous lesions or early-stage cancers with an excellent prognosis.
• 龐大的服務量能：僅在112至113年間，計畫就服務約480萬人次，從中發現超過63,000名癌症或癌前病變個案，對其健康進行了關鍵性的正向干預。Vast Service Capacity: Between 2023 and 2024 alone, the program served approximately 4.8 million people, identifying over 63,000 cases of cancer or precancerous lesions, leading to critical positive health interventions.

3.2 動態的政策演進：「健康台灣」戰略與計畫擴張 3.2 Dynamic Policy Evolution: The “Healthy Taiwan” Strategy and Program Expansion

台灣的篩檢計畫是一個不斷演進的動態體系。在「健康台灣」戰略下，此計畫迎來新一輪的重大擴張，展現出一個良性循環：執行產生數據 → 數據證明成效 → 政府基於實證加碼投資。 Taiwan’s screening program is a constantly evolving dynamic system. Under the “Healthy Taiwan” strategy, the program is undergoing a new round of major expansion, demonstrating a virtuous cycle: Implementation generates data → Data proves effectiveness → The government increases investment based on evidence.

• 預算倍增：自2025年起，癌症篩檢相關預算將從28億新台幣倍增至68億。Budget Doubling: Starting from 2025, the budget related to cancer screening will more than double from NT$2.8 billion to NT$6.8 billion.
• 宏大目標：目標在2030年將癌症死亡率降低三分之一。Ambitious Goal: The aim is to reduce cancer mortality by one-third by 2030.
• 服務擴大：具體內容包括放寬部分篩檢資格、擴大HPV檢測服務，並與成人健檢產生協同效應，提升整體效率。Service Expansion: Specifics include relaxing some screening eligibility criteria, expanding HPV testing services, and creating synergies with adult health check-ups to improve overall efficiency.

3.3 總結性專家評估 3.3 Concluding Expert Assessment

綜合分析，台灣的國家級五大癌症篩檢計畫是一項設計精良、執行到位且成效卓著的公共衛生典範。 In comprehensive analysis, Taiwan’s national five major cancer screening programs stand as a paradigm of well-designed, well-executed, and highly effective public health.

• 計畫優勢：Program Strengths:
  • 基於實證：篩檢工具均為國際公認的有效方法。Evidence-Based: Screening tools are all internationally recognized effective methods.
  • 精準風控：智慧的風險分層策略，提升資源配置效率。Precise Risk Management: Intelligent risk stratification strategies enhance resource allocation efficiency.
  • 健全追蹤：「主動追陽」系統與個管師制度，確保效益實現。Robust Follow-up: The proactive follow-up system and case manager institution ensure the realization of benefits.
  • 強力承諾：持續的政治與財政支持，確保計畫永續發展。Strong Commitment: Continuous political and financial support ensures the program’s sustainable development.
• 挑戰與未來方向：Challenges and Future Directions:
  • 提升參與率：持續克服民眾的心理與資訊障礙。Increasing Participation: Continuously overcoming public psychological and informational barriers.
  • 確保公平性：弭平偏鄉與弱勢族群的服務落差。Ensuring Equity: Bridging the service gap for rural and disadvantaged populations.
  • 科學調適：保持彈性，隨時準備納入新的篩檢技術。Scientific Adaptation: Maintaining flexibility to incorporate new screening technologies as they become available.

最終結論：總體而言，台灣的五大癌症篩檢計畫，憑藉其科學的頂層設計、精準的風險管理、人性化的個案追蹤以及穩固的政策支持，已成功地建立了一個能夠有效降低癌症衝擊的全國性防護網，可作為全球其他國家規劃癌症防治策略時，一個極具參考價值的成功模型。 Final Conclusion: Overall, through its scientific top-level design, precise risk management, humanized case follow-up, and solid policy support, Taiwan’s five major cancer screening programs have successfully established a national safety net that can effectively reduce the impact of cancer. It serves as a highly valuable success model for other countries in planning their cancer prevention and control strategies.